[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024)

March 2020 | 82 pages | ID: G5D77F20E3DEN
Daedal Research

US$ 900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Scope of the Report

The report entitled “Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024)” provides an in-depth analysis of the global TAVR market by value, by volume, by procedure, by region, etc. The reports also provides a regional analysis of the TAVR market, including the following regions: North America (The US & Rest of North America), Europe, Asia Pacific (China & Rest of Asia Pacific), Latin America, and Middle East & Africa.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall TAVR market has also been forecasted for the period 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global TAVR market is highly dominated with few major market players operating worldwide. The manufacturers of TAVR devices produce different types of devices for different applications. Further, the major players dominating the global TAVR market are Edwards Lifesciences Corporation, Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories. The four companies have been profiled in the report providing their business overview, financial overview and business strategies.

Country Coverage
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Company Coverage
  • Edwards Lifesciences Corporation
  • Medtronic plc
  • Boston Scientific Corporation
  • Abbott Laboratories
Executive Summary

Heart valve disease, one kind of structural heart diseases, is characterized by the damage or a defect in one of the four heart valves: aortic, pulmonary, mitral, and tricuspid valves. Heart valve disease normally falls under two categories: Stenosis and Regurgitation.

Aortic valve disease is a condition that occurs when the left ventricle and aorta (the main artery of the body) does not work properly. The aortic valve disease is mainly bifurcated into aortic stenosis (AS) and aortic regurgitation (AR). The AS treatment options include: balloon valvotomy, Surgical Aortic Valve Replacement (SAVR), and Transcatheter Aortic Valve Replacement (TAVR).

TAVR is a new minimally invasive approach for >65 years old population with intermediate to high surgical risk and patients ineligible for surgeries. TAVR is now expanding into patients with low to intermediate surgical risk. The risks and complications associated with TAVR include bleeding, vascular site complications, stroke, infection, acute kidney injury, heart attack, and even death.

The TAVR market can be segmented on the basis of procedure (Transfemoral Implantation, Transaortic Implantation, and Transapical Implantation), and Application (Aortic Stenosis and Aortic Regurgitation).

The global TAVR market has increased at a significant CAGR during the years 2015-2019 and projections are made that the market would rise in the next four years i.e. 2020-2024 tremendously. The TAVR market is expected to increase due to growing geriatric population, increasing prevalence of aortic stenosis (AS) and aortic regurgitation (AR), rapid urbanization, escalating healthcare expenditure, rising incidence of chronic diseases, etc. Yet the market faces some challenges such as economic slowdown, high cost involved, COVID-19 outbreak, risks and side effects associated with TAVR procedure, etc.
1. EXECUTIVE SUMMARY

2. INTRODUCTION

2.1 Heart Valve Disease: An Overview
2.2 Aortic Valve Disease: An Overview
  2.2.1 Current AS Treatment Options
2.3 Transcatheter Aortic Valve Replacement (TAVR): An Overview
  2.3.1 History of TAVR
  2.3.2 Difference Between TAVR & SAVR
  2.3.3 Risks and Complications Associated with TAVR
2.4 Transcatheter Aortic Valve Replacement (TAVR) Segmentation: An Overview
  2.4.1 TAVR Segmentation by Procedure and Application

3. GLOBAL MARKET ANALYSIS

3.1 Global TAVR Market: An Analysis
  3.1.1 Global TAVR Market by Value
  3.1.2 Global TAVR Market by Volume
  3.1.3 Global TAVR Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation)
  3.1.4 Global TAVR Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
  3.1.5 Global TAVR Market Volume by Region (The US, China, and ROW)
3.2 Global TAVR Market: Procedure Analysis
  3.2.1 Global Transfemoral TAVR Market by Value
  3.2.2 Global Transapical TAVR Market by Value
  3.2.3 Global Transaortic TAVR Market by Value

4. REGIONAL MARKET ANALYSIS

4.1 North America TAVR Market: An Analysis
  4.1.1 North America TAVR Market by Value
  4.1.2 North America TAVR Market by Region (The US and Rest of North America)
  4.1.3 The US TAVR Market by Value
  4.1.4 The US TAVR Market by Volume
  4.1.5 Rest of North America TAVR Market by Value
4.2 Europe TAVR Market: An Analysis
  4.2.1 Europe TAVR Market by Value
4.3 Asia Pacific TAVR Market: An Analysis
  4.3.1 Asia Pacific TAVR Market by Value
  4.3.2 Asia Pacific TAVR Market by Region (China and Rest of Asia Pacific)
  4.3.3 China TAVR Market by Value
  4.3.4 China TAVR Market by Volume
  4.3.5 Rest of Asia Pacific TAVR Market by Value
4.4 Middle East & Africa TAVR Market: An Analysis
  4.4.1 Middle East & Africa TAVR Market by Value
4.5 Latin America TAVR Market: An Analysis
  4.5.1 Latin America TAVR Market by Value

5. MARKET DYNAMICS

5.1 Growth Driver
  5.1.1 Growing Geriatric Population
  5.1.2 Escalating Healthcare Spending
  5.1.3 Rising Incidence of Chronic Diseases
  5.1.4 Increasing Prevalence of Aortic Stenosis (AS) & Aortic Regurgitation (AR)
  5.1.5 Rapid Urbanization
5.2 Challenges
  5.2.1 Economic Slowdown
  5.2.2 High Cost Involved
  5.2.3 Impact From COVID-19 Outbreak
  5.2.4 Risks and Side Effects Associated with TAVR Procedures
5.3 Market Trends
  5.3.1 Growing TAVR Eligible Patients
  5.3.2 Indication Expansion to Low-risk Patients
  5.3.3 Technological Advancements in TAVR Devices

6. COMPETITIVE LANDSCAPE

6.1 Global TAVR Market Players by Major Marketed TAVR Products
6.2 Global TAVR Market Players by TAVR Pipeline

7. COMPANY PROFILES

7.1 Edwards Lifesciences Corporation
  7.1.1 Business Overview
  7.1.2 Financial Overview
  7.1.3 Business Strategy
7.2 Medtronic plc
  7.2.1 Business Overview
  7.2.2 Financial Overview
  7.2.3 Business Strategy
7.3 Boston Scientific Corporation
  7.3.1 Business Overview
  7.3.2 Financial Overview
  7.3.3 Business Strategy
7.4 Abbott Laboratories
  7.4.1 Business Overview
  7.4.2 Financial Overview
  7.4.3 Business Strategy

LIST OF FIGURES

Figure 1: Current AS Treatment Options
Figure 2: History of TAVR
Figure 3: Risks and Complications Associated with TAVR
Figure 4: TAVR Segmentation by Procedure and Application
Figure 5: Global TAVR Market by Value; 2015-2019 (US$ Billion)
Figure 6: Global TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 7: Global TAVR Market by Volume; 2015-2019 (Thousand)
Figure 8: Global TAVR Market by Volume; 2020-2024 (Thousand)
Figure 9: Global TAVR Market by Procedure; 2019 (Percentage, %)
Figure 10: Global TAVR Market by Region; 2019 (Percentage, %)
Figure 11: Global TAVR Market Volume by Region; 2019 (Percentage, %)
Figure 12: Global Transfemoral TAVR Market by Value; 2017-2019 (US$ Billion)
Figure 13: Global Transfemoral TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 14: Global Transapical TAVR Market by Value; 2017-2019 (US$ Million)
Figure 15: Global Transapical TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 16: Global Transaortic TAVR Market by Value; 2017-2019 (US$ Billion)
Figure 17: Global Transaortic TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 18: North America TAVR Market by Value; 2017-2019 (US$ Billion)
Figure 19: North America TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 20: North America TAVR Market by Region; 2019 (Percentage, %)
Figure 21: The US TAVR Market by Value; 2017-2019 (US$ Billion)
Figure 22: The US TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 23: The US TAVR Market by Volume; 2017-2019 (Thousand)
Figure 24: The US TAVR Market by Volume; 2020-2024 (Thousand)
Figure 25: Rest of North America TAVR Market by Value; 2017-2019 (US$ Million)
Figure 26: Rest of North America TAVR Market by Value; 2020-2024 (US$ Million)
Figure 27: Europe TAVR Market by Value; 2017-2019 (US$ Billion)
Figure 28: Europe TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 29: Asia Pacific TAVR Market by Value; 2017-2019 (US$ Million)
Figure 30: Asia Pacific TAVR Market by Value; 2020-2024 (US$ Billion)
Figure 31: Asia Pacific TAVR Market by Region; 2019 (Percentage, %)
Figure 32: China TAVR Market by Value; 2017-2019 (US$ Million)
Figure 33: China TAVR Market by Value; 2020-2024 (US$ Million)
Figure 34: China TAVR Market by Volume; 2017-2019 (Thousand)
Figure 35: China TAVR Market by Volume; 2020-2024 (Thousand)
Figure 36: Rest of Asia Pacific TAVR Market by Value; 2017-2019 (US$ Million)
Figure 37: Rest of Asia Pacific TAVR Market by Value; 2020-2024 (US$ Million)
Figure 38: Middle East & Africa TAVR Market by Value; 2017-2019 (US$ Million)
Figure 39: Middle East & Africa TAVR Market by Value; 2020-2024 (US$ Million)
Figure 40: Latin America TAVR Market by Value; 2017-2019 (US$ Million)
Figure 41: Latin America TAVR Market by Value; 2020-2024 (US$ Million)
Figure 42: Global Aging Population by Region; 2010-2040 (Percentage, %)
Figure 43: Global Healthcare Spending; 2017-2022 (US$ Billion)
Figure 44: The US Chronic Diseases Growth Rates; 2016-2025 (Percentage, %)
Figure 45: Global Prevalence of Aortic Stenosis (AS) and Aortic Regurgitation (AR); 2017-2025 (Million)
Figure 46: Global Urbanization Rates by Region; 2010-2040 (Percentage, %)
Figure 47: Global GDP Growth; 2017-2020 (Percentage, %)
Figure 48: Global Eligible Patients for TAVR; 2017-2025 (Thousand)
Figure 49: Edwards Lifesciences Corporation Net Sales; 2015-2019 (US$ Billion)
Figure 50: Edwards Lifesciences Corporation Net Sales by Product Group; 2019 (Percentage, %)
Figure 51: Edwards Lifesciences Corporation Net Sales by Region; 2019 (Percentage, %)
Figure 52: Medtronic plc Net Sales; 2015-2019 (US$ Billion)
Figure 53: Medtronic plc Net Sales by Segments; 2019 (Percentage, %)
Figure 54: Medtronic plc Net Sales by Region; 2019 (Percentage, %)
Figure 55: Boston Scientific Corporation Net Sales; 2015-2019 (US$ Billion)
Figure 56: Boston Scientific Corporation Net Sales by Segments; 2019 (Percentage, %)
Figure 57: Boston Scientific Corporation Net Sales by Region; 2019 (Percentage, %)
Figure 58: Abbott Laboratories Net Sales; 2015-2019 (US$ Billion)
Figure 59: Abbott Laboratories Net Sales by Segments; 2019 (Percentage, %)
Figure 60: Abbott Laboratories Net Sales by Region; 2019 (Percentage, %)
Table 1: Difference Between TAVR & SAVR
Table 2: Global TAVR Market Players by Major Marketed TAVR Products
Table 3: Global TAVR Market Players by TAVR Pipeline


More Publications